Alligator Bioscience, a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today provided a brief update regarding mitazalimab.
In parallel with ongoing partnering activities, Alligator is exploring alternative opportunities for phase 3 development of mitazalimab in first line metastatic pancreatic cancer. As part of these efforts, Alligator has signed a letter-of-intent with the French non-for-profit clinical cancer research organization Unicancer. Consequently, the parties are collaborating to establish the feasibility of, and prepare for, a global investigator sponsored Phase 3 study.
No development decisions have been taken at this time, and any such activities remain at an exploratory stage.
Team Health Accessible
Health & Wellness Editorial Team
HealthAccessible editorial team delivers trusted, accessible, and evidence-based health information for everyone.
